Bipolar Mania News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA Approves Iloperidone (Fanapt) for Acute Treatment of Bipolar I Disorder

The FDA approved iloperidone for acute treatment of bipolar I disorder on April 02, 2024, according to Vanda Pharmaceuticals.

Mihaelh polymeropoulosRosarelis torresVanda pharmaceuticals recent newsDrug administrationVanda pharmaceuticalsVanda pharmaceuticals onVanda pharmaceuticalYoung mania rating scaleClinical global impressions severityClinical global impressionMayo clinicVanda pharmaceutical fanaptAcute treatmentVanda pharmaceuticals recentBipolar maniaEarlier decision

FDA Approves Fanapt for Mixed, Manic Episodes Associated With Bipolar I Disorder

The atypical antipsychotic was approved for the acute treatment of schizophrenia in 2009.

United statesStephen stahlMihaelh polymeropoulosVanda pharmaceuticalsUniversity of california san diegoVanda pharmaceuticals incDrug administrationYoung mania rating scaleClinician global impressionCalifornia san diegoPharmaceutical fanaptBipolar maniaPlacebo controlled study

Vanda Pharmaceuticals Announces The Publication Of Efficacy And Safety Of Iloperidone In Bipolar Mania: A Double-Blind, Placebo-Controlled Study In Th

Vanda Pharmaceuticals Announces The Publication Of Efficacy And Safety Of Iloperidone In Bipolar Mania: A Double-Blind, Placebo-Controlled Study In Th
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesKevin moranDrug administrationVanda pharmaceuticals incPrnewswire vanda pharmaceuticals incBipolar maniaClinical psychiatryNew drug applicationPrescription drug user fee actBoxed warningsImportant safety informationVice presidentChief financial officer

Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry -January 17, 2024 at 03:47 pm EST

WASHINGTON, Jan. 17, 2024 /PRNewswire/ Vanda Pharmaceuticals Inc. today announced the publication of an article titled Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind,.

United statesKevin moranDrug administrationPrnewswire vanda pharmaceuticals incVanda pharmaceuticals incBipolar maniaNew drug applicationPrescription drug user fee actBoxed warningsImportant safety informationVice presidentChief financial officer

Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry

/PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "Efficacy and Safety of Iloperidone in.

United statesKevin moranPrnewswire vanda pharmaceuticals incVanda pharmaceuticals incDrug administrationBipolar maniaNew drug applicationPrescription drug user fee actBoxed warningsImportant safety informationVice presidentChief financial officerVanda pharmaceuticals inc